CA2192418C - New crystal modification of cdch, a process for its preparation and pharmaceutical formulations comprising this modification - Google Patents

New crystal modification of cdch, a process for its preparation and pharmaceutical formulations comprising this modification Download PDF

Info

Publication number
CA2192418C
CA2192418C CA002192418A CA2192418A CA2192418C CA 2192418 C CA2192418 C CA 2192418C CA 002192418 A CA002192418 A CA 002192418A CA 2192418 A CA2192418 A CA 2192418A CA 2192418 C CA2192418 C CA 2192418C
Authority
CA
Canada
Prior art keywords
cdch
monohydrate
crystals
water
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002192418A
Other languages
English (en)
French (fr)
Other versions
CA2192418A1 (en
Inventor
Alfons Grunenberg
Patrick Bosche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7779831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2192418(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG filed Critical Bayer AG
Publication of CA2192418A1 publication Critical patent/CA2192418A1/en
Application granted granted Critical
Publication of CA2192418C publication Critical patent/CA2192418C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002192418A 1995-12-12 1996-12-09 New crystal modification of cdch, a process for its preparation and pharmaceutical formulations comprising this modification Expired - Lifetime CA2192418C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19546249.1 1995-12-12
DE19546249A DE19546249A1 (de) 1995-12-12 1995-12-12 Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen

Publications (2)

Publication Number Publication Date
CA2192418A1 CA2192418A1 (en) 1997-06-13
CA2192418C true CA2192418C (en) 2001-06-12

Family

ID=7779831

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002192418A Expired - Lifetime CA2192418C (en) 1995-12-12 1996-12-09 New crystal modification of cdch, a process for its preparation and pharmaceutical formulations comprising this modification

Country Status (42)

Country Link
US (1) US5849752A (Direct)
EP (1) EP0780390B1 (Direct)
JP (1) JP4104687B2 (Direct)
KR (1) KR100525146B1 (Direct)
CN (1) CN1061348C (Direct)
AR (1) AR005009A1 (Direct)
AT (1) ATE221531T1 (Direct)
AU (1) AU708006B2 (Direct)
BG (1) BG62258B1 (Direct)
BR (1) BR9605968A (Direct)
CA (1) CA2192418C (Direct)
CO (1) CO4480105A1 (Direct)
CU (1) CU22774A3 (Direct)
CZ (1) CZ288657B6 (Direct)
DE (2) DE19546249A1 (Direct)
DK (1) DK0780390T3 (Direct)
EE (1) EE03474B1 (Direct)
ES (1) ES2179910T3 (Direct)
HR (1) HRP960558B1 (Direct)
HU (1) HU226521B1 (Direct)
ID (1) ID22625A (Direct)
IL (1) IL119795A (Direct)
IN (1) IN185805B (Direct)
MA (1) MA24342A1 (Direct)
MY (1) MY117492A (Direct)
NL (1) NL300109I1 (Direct)
NO (1) NO306725B1 (Direct)
NZ (1) NZ299905A (Direct)
PL (1) PL184885B1 (Direct)
PT (1) PT780390E (Direct)
RO (1) RO119782B1 (Direct)
RU (1) RU2162468C2 (Direct)
SA (1) SA96170492B1 (Direct)
SG (1) SG47201A1 (Direct)
SI (1) SI0780390T1 (Direct)
SK (1) SK282805B6 (Direct)
SV (1) SV1996000109A (Direct)
TR (1) TR199600970A2 (Direct)
TW (1) TW411340B (Direct)
UA (1) UA35638C2 (Direct)
YU (1) YU49485B (Direct)
ZA (1) ZA9610405B (Direct)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ503538A (en) * 1997-09-25 2001-03-30 Bayer Ag Moxifloxacin formulation characterised by the release times containing hydroxypropylmethylcellulose or polyvinylpyrrolidone as binder and ethylcellulose as film forming polymer
DE19751948A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
ID29089A (id) * 1998-11-10 2001-07-26 Bayer Ag Sediaan farmasi moksifloksasin
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) * 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
US20060252789A1 (en) * 2002-10-31 2006-11-09 Sujay Biswas Amorphous moxifloxacin hydrochloride
DE602004022646D1 (de) † 2003-04-09 2009-10-01 Reddys Lab Ltd Dr Kristalline form iii von wasserfreiem moxifloxacin-hydrochlorid und ein verfahren zu seiner herstellung
WO2005012285A1 (en) * 2003-08-05 2005-02-10 Matrix Laboratories Ltd An improved process for the preparation of moxifloxacin hydrochloride
ITMI20032259A1 (it) 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
DE602004018370D1 (de) * 2003-11-20 2009-01-22 Chemi Spa Polymorphe von 1-cyclopropyl-7-(äs,sü - 2,8-diazadicyclo ä4.3.0ü non-8-yl) -6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäurehydrochlorid und verfahren zu deren herstellung
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
DE102004015981A1 (de) * 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
DE602007003024D1 (de) 2006-06-27 2009-12-10 Sandoz Ag Neues verfahren zur salzherstellung
ES2303768B1 (es) * 2006-09-08 2009-06-05 Quimica Sintetica, S.A. Nueva forma cristalina de moxifloxacino clorhidrato.
WO2008059223A2 (en) * 2006-11-13 2008-05-22 Cipla Limited Process for the synthesis of moxifloxacin hydrochloride
EP1992626A1 (en) * 2007-05-10 2008-11-19 Sandoz AG Process for the preparation of moxifloxacin hydrochloride
EP2083010A1 (en) * 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
CN102176902B (zh) 2008-10-09 2012-10-31 阿卜迪易卜拉欣贸易公司 有机溶剂在莫西沙星湿法造粒中的应用
WO2010052726A1 (en) * 2008-11-06 2010-05-14 Hetero Research Foundation Novel polymorph of moxifloxacin hydrochloride
US20110293717A1 (en) 2008-12-08 2011-12-01 Ratiopharm Gmbh Compacted moxifloxacin
JP2012526793A (ja) 2009-05-15 2012-11-01 レッドエックス ファーマ リミテッド 酸化還元薬物誘導体
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN102924449B (zh) * 2012-10-30 2015-08-12 重庆福安药业集团庆余堂制药有限公司 盐酸莫西沙星h晶型及其制备方法和药物组合物
CA2893534A1 (en) 2012-12-04 2014-06-12 Mankind Research Centre An improved process for the preparation of moxifloxacin hydrochloride
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
CA2904387C (en) 2013-03-15 2021-12-07 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601567A1 (de) * 1986-01-21 1987-07-23 Bayer Ag 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate
EP0241206A3 (en) * 1986-03-31 1989-05-10 Sankyo Company Limited Quinoline-3-carboxylic acid derivatives, their preparation and use
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
TW209865B (Direct) 1992-01-10 1993-07-21 Bayer Ag
ATE207479T1 (de) * 1992-01-31 2001-11-15 Chugai Pharmaceutical Co Ltd Kristalle von derivaten von chinozon carbonsäure- hydraten
DE4234078A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
CA2112165C (en) * 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
ZA946853B (en) * 1993-09-10 1995-04-24 Daiichi Seiyaku Co Crystals of antimicrobial compound.
ATE170400T1 (de) * 1994-04-07 1998-09-15 Pfizer Verwendung von trovafloxacin oder dessen derivaten zur herstellung eines arzneimittels zur behandlung von h.pylori infektionen

Also Published As

Publication number Publication date
PL184885B1 (pl) 2003-01-31
NZ299905A (en) 1998-09-24
TW411340B (en) 2000-11-11
MY117492A (en) 2004-07-31
CO4480105A1 (es) 1997-07-09
AR005009A1 (es) 1999-04-07
BG101043A (en) 1998-04-30
HU9603428D0 (en) 1997-01-28
RO119782B1 (ro) 2005-03-30
KR970042550A (ko) 1997-07-24
CZ364696A3 (en) 1997-07-16
RU2162468C2 (ru) 2001-01-27
JPH09169757A (ja) 1997-06-30
JP4104687B2 (ja) 2008-06-18
CA2192418A1 (en) 1997-06-13
EE9600201A (et) 1997-06-16
DE19546249A1 (de) 1997-06-19
HUP9603428A3 (en) 1997-10-28
YU49485B (sh) 2006-08-17
ATE221531T1 (de) 2002-08-15
CN1061348C (zh) 2001-01-31
AU708006B2 (en) 1999-07-29
KR100525146B1 (ko) 2006-01-27
EP0780390B1 (de) 2002-07-31
ID22625A (id) 1999-12-02
CZ288657B6 (cs) 2001-08-15
HUP9603428A2 (en) 1997-08-28
HRP960558B1 (en) 2002-04-30
MA24342A1 (fr) 1998-07-01
MX9606325A (es) 1997-10-31
CU22774A3 (es) 2002-07-24
HU226521B1 (en) 2009-03-30
PL317415A1 (en) 1997-06-23
CN1160052A (zh) 1997-09-24
SA96170492B1 (ar) 2006-05-23
NO965298D0 (no) 1996-12-11
YU65096A (sh) 1998-12-23
US5849752A (en) 1998-12-15
SK282805B6 (sk) 2002-12-03
TR199600970A2 (tr) 1997-06-21
EP0780390A1 (de) 1997-06-25
IL119795A (en) 1998-12-27
HRP960558A2 (en) 1998-02-28
BR9605968A (pt) 1998-08-18
DK0780390T3 (da) 2002-11-11
NO965298L (no) 1997-06-13
IN185805B (Direct) 2001-05-05
SV1996000109A (es) 1997-10-23
SK159196A3 (en) 1997-10-08
ES2179910T3 (es) 2003-02-01
DE59609501D1 (de) 2002-09-05
SI0780390T1 (en) 2002-10-31
BG62258B1 (bg) 1999-06-30
IL119795A0 (en) 1997-03-18
ZA9610405B (en) 1997-06-23
SG47201A1 (en) 1998-03-20
EE03474B1 (et) 2001-08-15
NL300109I1 (nl) 2003-02-03
UA35638C2 (uk) 2001-04-16
NO306725B1 (no) 1999-12-13
AU7421696A (en) 1997-06-19
PT780390E (pt) 2002-11-29

Similar Documents

Publication Publication Date Title
CA2192418C (en) New crystal modification of cdch, a process for its preparation and pharmaceutical formulations comprising this modification
DE3378827D1 (en) Cephalosporin derivatives and process for their preparation
CA2213714A1 (en) Phenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
RU95110937A (ru) Хинолоновые и акридиноновые соединения, способ их получения, фармацевтическая композиция и промежуточные соединения
WO2009138847A2 (en) An improved process for the preparation of cefozopran
CA2010639A1 (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2-thiones
NO842318L (no) Fremgangsmaate for fremstilling av krystallinsk natrium-amoksycillin
GB2200355A (en) Potassium clavulanate
RU2418806C2 (ru) Получение кристаллического антибиотика
HUT49614A (en) Process for producing cefalosporin derivatives and pharmaceutical compositions comprising these compounds
CN101347412B (zh) 三水合氨磷汀结晶冻干制剂及其制备方法
KR870001071B1 (ko) 고 결정성 나트륨 세포페라존의 제조방법
CA2656711A1 (en) Novel hydrate form of moxifloxacin monohydrochloride
US4532253A (en) Oxaprozin calcium salt pharmaceutical compositions
EP0262207B1 (en) Beta-lactam antibiotics
RU2074858C1 (ru) Кристаллический дигидрат (5r, 6s)-2-карбамоилоксиметил-6-[(1r)-гидроксиэтил]-2-пенем-3-карбоновой кислоты, способ его получения, фармацевтическая композиция
KR860001495B1 (ko) 결정성 나트륨 세포페라존의 제조방법
BG65240B1 (bg) Кристална полиморфна форма на азабицикло (2,2,2) октан-3-амин цитрат и фармацевтичен състав, който я съдържа, метод за получаване и използването
ES8103031A1 (es) Procedimiento para la obtencion de nuevos derivados de gua- nidina
IE873144L (en) Substituted thienoimidazole-toluidine derivatives, a process¹for their preparation, pharmaceutical compositions¹containing them, and their use as inhibitors of gastric acid¹secretion
CN101284830A (zh) 1-甲基碳青霉烯化合物的结晶
CN110314143A (zh) 注射用右旋奥拉西坦冻干制剂及其制备方法
WO2024147727A1 (es) Sintesis de fosfomicina disódica
CA1089447A (en) Sodium cefamandole crystalline forms
TH20903B (th) รูปผลึกดัดแปลงใหม่ cdch กระบวนการสำหรับเตรียมรูปดัดแปลงนี้และสารผสมตามสูตรทางเภสัชกรรมที่ประกอบด้วยรูปนี้

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20161209